# Case Clinical Trials Unit

> **NIH NIH UM1** · CASE WESTERN RESERVE UNIVERSITY · 2024 · $2,393,908

## Abstract

ABSTRACT
The Case Clinical Trials Unit (CTU) comprises three highly productive clinical research sites: Case/UHC in
Cleveland, the University of Cincinnati, and the Joint Clinical Research Center in Kampala. Each of these
three sites is a top performing ACTG treatment trial site with excellent accruals, outstanding performance
evaluations and major roles in the leadership of the network and it is scientific productivity. A key theme of
this CTU is the close link of our clinical research portfolio with our basic and translational research
programs. Thus, the three CRS sites of the Case CTU bring a comprehensive research plan to the
enterprise. Led by faculty who are national and international leaders in their fields, these units are poised
to make substantive contributions to each of the priority areas targeted by the ACTG: Inflammation/End
Organ Disease, Antiretroviral Medications, HIV Eradication and Cure, Tuberculosis, and Hepatitis. The
Case/UHC CRS has also been a productive member of the HVTN. The Case/UHC CRS has been a high-
performing site in this network, having enrolled participants, including some from difficult-to-reach segments
of the population, into multiple HVTN trials during this funding cycle. In some cases, enrollment has
substantially exceeded expectations from the site. Additionally, Case CTU investigators are highly
accomplished researchers who have extensive experience in the monitoring of immune responses form
immunization, in evaluating diverse immunization strategies to enhance vaccine responsiveness, and in
the use of vaccine responsiveness as a readout of immune competence. The University of Cincinnati CRS
is a highly efficient, well-managed CRS that has been conducting clinical and translational research for the
ACTG since 1987, and is the number 1 site by number of participants enrolled in the US. In addition to their
extraordinary performance on enrollments, the site has extensive accumulated expertise in the metabolic
complications of HIV, and is additionally a high-performing protocol-specific HPTN site. The JCRC is one
of the top-performing international sites in the ACTG, and is the critical component in the contributions of
the Case CTU to the tuberculosis agenda. It is also the site of the first hepatitis C treatment clinical trial in
Africa, the ACTG A5360 protocol. The JCRC CRS has also previously demonstrated its ability to access
large numbers of subjects in well-defined populations at high risk for HIV infection, having been the site of
the first HIV vaccine trial in Africa, and can begin contributing to the HIV prevention networks immediately
as well if selected as a site. Thus, the three CRS that comprise this CTU are positioned to provide sustained
leadership and contribution to the treatment and prevention agenda of the NIAID Networks.

## Key facts

- **NIH application ID:** 10746412
- **Project number:** 5UM1AI069501-18
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** JEFFREY M. JACOBSON
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,393,908
- **Award type:** 5
- **Project period:** 2007-02-13 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10746412

## Citation

> US National Institutes of Health, RePORTER application 10746412, Case Clinical Trials Unit (5UM1AI069501-18). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10746412. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*